Jemperli (dostarlimab-gxly) plus chemotherapy approved in the …
WEBJul 31, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR ...
GSK blows Jemperli marching horn against Keytruda with new …
WEBAug 1, 2024 · On Thursday, the FDA expanded the endometrial cancer use for GSK’s Jemperli, used in combination with chemotherapy, to include patients with mismatch repair proficient (pMMR) or...
Jemperli (dostarlimab) trial continues to show unprecedented ... - GSK
WEBJun 3, 2024 · GSK plc (LSE/NYSE: GSK) today announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center (MSK) evaluating Jemperli (dostarlimab) as a first-line treatment—as an alternative to surgery—for mismatch repair deficient (dMMR) locally advanced rectal cancer.
GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the …
WEBDec 11, 2023 · GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer. Download (PDF, 195.8KB) European Commission also converts previous conditional approval for Jemperli to full approval as a monotherapy for ...
FDA approves dostarlimab-gxly with chemotherapy for …
WEBOn July 31, 2023, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary...
US FDA expands Jemperli (dostarlimab) plus chemotherapy approval ... - GSK
WEBAug 1, 2024 · GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel (chemotherapy) followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This approval broadens the previous ...
Glaxo's (GSK) Jemperli Gets FDA Approval for New Indication - Yahoo Finance
WEBAug 18, 2021 · The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating patients with mismatch repair-deficient recurrent/advanced solid tumors. This is the second approved indication for the...
FDA Approves Immunotherapy for Endometrial Cancer with …
WEBApr 22, 2021 · Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or...
GSK Gets FDA Approval for Jemperli Use With Chemo to Treat …
WEBJul 31, 2023 · US regulators have cleared GSK Plc’s Jemperli drug in combination with chemotherapy as a frontline treatment for a particular type of endometrial cancer, boosting the drug’s blockbuster ...
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
WEB5 days ago · In iTeos’ news release of the data drop, the partners called this effect a “clinically meaningful improvement,” noting that it represented an increase of around 30% versus Jemperli (dostarlimab) alone. ... Jemperli monotherapy counterparts, on the other hand, saw a 65% dip in circulating tumor DNA during this time frame. GSK and iTeos ...